IOL Chemicals Posts Record Q2 FY27 Results Driven by Margin Expansion
IOL Chemicals & Pharmaceuticals Ltd · Press Release · 31 Oct 2026, 1:37 am
IOL Chemicals Posts Record Q2 FY27 Results Driven by Margin Expansion IOL Chemicals reported record standalone Q2 FY27 revenue of ₹795.0 Cr, up 40.1% YoY, with EBITDA surging 79.6% YoY to ₹114.9 Cr. EBITDA margin expanded 321 bps YoY to 14.4%, supported by better product mix and operating efficiencies. PAT jumped 116.8% YoY to ₹65.0 Cr, with PAT margin rising 290 bps to 8.1%. Pharmaceuticals revenue reached ₹472.8 Cr, with non-Ibuprofen sales growing ~70% YoY to contribute 45% of segment revenue. Chemicals revenue rose to ₹322.3 Cr, driven by improved realisations.
Original exchange filing (PDF)
More announcements from IOL Chemicals & Pharmaceuticals Ltd
- Clarification on increase in Volume · 11 Nov 2026
- The Exchange has sought clarification from IOL Chemicals & Pharmaceuticals Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. · 11 Nov 2026
- Transcript of Earning Call on the Q2 & H1 FY27 Financial Results · 05 Nov 2026
- Audio Recording of Earnings Call on the Q2 & H1 FY 27 Financial Results · 02 Nov 2026
- Investor Presentation- Q2 & H1 FY27 · 02 Nov 2026
- Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 · 30 Oct 2026
- Submission of Financial Results · 30 Oct 2026
- IOL Chemicals and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 30 Oct 2026
